Charlotte Nelissen1, Maarten Lambrecht2, Frederik Nevens3, Dirk Van Raemdonck4, Johan Vanhaecke5, Dirk Kuypers6, Jacques Pirenne7, Sandra Nuyts8. 1. Department of Radiation Oncology, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: Charlotte.nelissen@uzleuven.be. 2. Department of Radiation Oncology, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: Maarten.lambrecht@uzleuven.be. 3. Department of Hepatology, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: Frederik.nevens@uzleuven.be. 4. Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: Dirk.vanraemdonck@uzleuven.be. 5. Department of Cardiology, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: johan.vanhaecke@uzleuven.be. 6. Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: dirk.kuypers@uzleuven.be. 7. Department of Abdominal Transplant Surgery, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: Jacques.pirenne@uzleuven.be. 8. Department of Radiation Oncology, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. Electronic address: sandra.nuyts@uzleuven.be.
Abstract
BACKGROUND: We investigated the incidence and survival of non-cutaneous head and neck cancer (HNC) after solid organ transplantation and identified prognostic factors impacting the outcome after treatment. METHODS: A retrospective analysis of patients who underwent solid organ transplantation in our institution between 1987 and 2012. RESULTS: Of 5255 organ transplant patients, 48 recipients (0.9%) developed HNC in the posttransplant follow-up period. Liver transplant recipients showed the highest risk. Median follow-up of cancer patients was 46.7 months (range 2.9-256.2 months). Three-year overall survival and disease free survival (DFS) were 70% and 53%. Locoregional control was 67% and 48% at 3 and 5 years, respectively. Smoking and initial AJCC stage were two significant prognostic factors influencing DFS. CONCLUSIONS: Non-cutaneous HNC is rare in transplant recipients, but slightly more common after liver transplantation. Outcome after treatment is poor with locoregional recurrence being the main problem. Screening of high risk groups might be relevant.
BACKGROUND: We investigated the incidence and survival of non-cutaneous head and neck cancer (HNC) after solid organ transplantation and identified prognostic factors impacting the outcome after treatment. METHODS: A retrospective analysis of patients who underwent solid organ transplantation in our institution between 1987 and 2012. RESULTS: Of 5255 organ transplant patients, 48 recipients (0.9%) developed HNC in the posttransplant follow-up period. Liver transplant recipients showed the highest risk. Median follow-up of cancerpatients was 46.7 months (range 2.9-256.2 months). Three-year overall survival and disease free survival (DFS) were 70% and 53%. Locoregional control was 67% and 48% at 3 and 5 years, respectively. Smoking and initial AJCC stage were two significant prognostic factors influencing DFS. CONCLUSIONS: Non-cutaneous HNC is rare in transplant recipients, but slightly more common after liver transplantation. Outcome after treatment is poor with locoregional recurrence being the main problem. Screening of high risk groups might be relevant.